BRPI0417206A - forma cristalina de 2-{4-3-(4-cloro-2-fluorofenil)-4-pirimidin-4-il-1h-pirazo l-5-il]piperidin-1-il}-2-oxoetanol - Google Patents
forma cristalina de 2-{4-3-(4-cloro-2-fluorofenil)-4-pirimidin-4-il-1h-pirazo l-5-il]piperidin-1-il}-2-oxoetanolInfo
- Publication number
- BRPI0417206A BRPI0417206A BRPI0417206-0A BRPI0417206A BRPI0417206A BR PI0417206 A BRPI0417206 A BR PI0417206A BR PI0417206 A BRPI0417206 A BR PI0417206A BR PI0417206 A BRPI0417206 A BR PI0417206A
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline form
- oxoethanol
- pyrimidin
- piperidin
- fluorophenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
"FORMA CRISTALINA DE 2-{4-3-(4-CLORO-2-FLUOROFENIL)-4-PIRIMIDIN-4-IL-1H-PIRAZO L-5-IL!PIPERIDIN-1-IL)-2-OXOETANOL". Forma cristalina do inibidor de p38 cinase 2-{4-¢3-(4-cloro-2-fluorofenil)-4-pirimidin-4-il-1H-pirazol-5-íi!piperidin-1- il}-2-oxoetanol é fornecido. A forma cristalina é uma forma cristalina hidratada. Também fornecidas são combinações e composições farmacêuticas compreendendo a forma cristalina, processo para preparo da forma cristalina e para preparo de composições compreendendo a forma cristalina, e métodos para a profilaxia e/ou tratamento da condição mediada por p38 cinase compreendendo administração a um indivíduo de uma quantidade terapeuticamente eficaz da forma cristalina de 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53076303P | 2003-12-19 | 2003-12-19 | |
PCT/IB2004/004187 WO2005061486A1 (en) | 2003-12-19 | 2004-12-15 | Crystalline form of 2-{4-‘3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1h-pyrazol-5-yl!piperidin-1-yl}-2-oxoethanol |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0417206A true BRPI0417206A (pt) | 2007-02-06 |
Family
ID=34710178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0417206-0A BRPI0417206A (pt) | 2003-12-19 | 2004-12-15 | forma cristalina de 2-{4-3-(4-cloro-2-fluorofenil)-4-pirimidin-4-il-1h-pirazo l-5-il]piperidin-1-il}-2-oxoetanol |
Country Status (7)
Country | Link |
---|---|
US (1) | US20070142412A1 (pt) |
EP (1) | EP1697346A1 (pt) |
JP (1) | JP2007514734A (pt) |
BR (1) | BRPI0417206A (pt) |
CA (1) | CA2550283A1 (pt) |
MX (1) | MXPA06006813A (pt) |
WO (1) | WO2005061486A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1511743A1 (en) * | 2002-06-05 | 2005-03-09 | Pharmacia Corporation | Pyrazole-derivatives as p38 kinase inhibitors |
CL2004000366A1 (es) * | 2003-02-26 | 2005-01-07 | Pharmacia Corp Sa Organizada B | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. |
-
2004
- 2004-12-15 EP EP04801407A patent/EP1697346A1/en not_active Withdrawn
- 2004-12-15 MX MXPA06006813A patent/MXPA06006813A/es not_active Application Discontinuation
- 2004-12-15 WO PCT/IB2004/004187 patent/WO2005061486A1/en active Application Filing
- 2004-12-15 BR BRPI0417206-0A patent/BRPI0417206A/pt not_active Application Discontinuation
- 2004-12-15 US US10/583,460 patent/US20070142412A1/en not_active Abandoned
- 2004-12-15 JP JP2006544594A patent/JP2007514734A/ja not_active Withdrawn
- 2004-12-15 CA CA002550283A patent/CA2550283A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2005061486A1 (en) | 2005-07-07 |
MXPA06006813A (es) | 2006-12-19 |
JP2007514734A (ja) | 2007-06-07 |
CA2550283A1 (en) | 2005-07-07 |
US20070142412A1 (en) | 2007-06-21 |
EP1697346A1 (en) | 2006-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009000333A (es) | Pirrilopirimidinas para composiciones farmaceuticas. | |
GEP20115302B (en) | Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5- trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide | |
NO20081315L (no) | Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser | |
MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
UA86614C2 (ru) | Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата | |
SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
TW200500358A (en) | Compounds | |
NO20073465L (no) | Benzotiazol-derivater | |
NO20084418L (no) | Azolopyridin-3-on derivater som inhibitorer av endoteliallipase | |
IL166412A0 (en) | Novel use of benzothiazole derivatives | |
TW200722081A (en) | New therapeutic combinations for the treatment or prevention of depression | |
IL205697A0 (en) | 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof | |
NO20085271L (no) | Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni | |
MY147643A (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder | |
GB0112348D0 (en) | Compounds | |
MY143568A (en) | 11b-hsd1 inhibitors for the treatment of diabetes | |
NO20091185L (no) | Piperidinderivater | |
TNSN04165A1 (en) | Substituted hydroxyethylamines | |
NO20064951L (no) | 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse | |
SE0301232D0 (sv) | Novel use | |
DE60306546D1 (de) | Entzündungshemmende 3-arylthio-3-thiazolylalkylamine | |
NO20034301L (no) | Cyano-substituerte dihydropyrimidin forbindelser | |
WO2005110413A3 (en) | Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions | |
BR0315462A (pt) | Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação | |
SE0302756D0 (sv) | Novel Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |